Search research articles
Contact Us
Filters
Showing results (471-480 of 643) with videos related to
Page
of 65
Sort By:
Advances in Therapy
|
July 9, 2021
Pembrolizumab in Patients with Refractory Cutaneous Squamous Cell Carcinoma: A Phase II Trial
Renata Ferrarotto, Luana G Sousa, Yun Qing, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 25, 2022
Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib Study
Funda Meric-Bernstam, Randy F Sweis, Stefan Kasper, et al.
NPJ Precision Oncology
|
July 15, 2023
Actionability classification of variants of unknown significance correlates with functional effect
Amber Johnson, Patrick Kwok-Shing Ng, Michael Kahle, et al.
Cancer Discovery
|
February 15, 2024
Co-clinical Trial of Novel Bispecific Anti-HER2 Antibody Zanidatamab in Patient-Derived Xenografts
Timothy P DiPeri, Kurt W Evans, Bailiang Wang, et al.
International Journal of Cancer
|
November 13, 2019
Phase II, 2-stage, 2-arm, PIK3CA mutation stratified trial of MK-2206 in recurrent endometrial cancer
Andrea P Myers, Panagiotis A Konstantinopoulos, William T Barry, et al.
Investigational New Drugs
|
October 28, 2017
Radiomics to predict immunotherapy-induced pneumonitis: proof of concept
Rivka R Colen, Takeo Fujii, Mehmet Asim Bilen, et al.
American Journal of Cancer Research
|
January 8, 2021
KRT-232 and navitoclax enhance trametinib's anti-Cancer activity in non-small cell lung cancer patient-derived xenografts with KRAS mutations
Xiaoshan Zhang, Ran Zhang, Huiqin Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 6, 2018
Cyclin E Overexpression Sensitizes Triple-Negative Breast Cancer to Wee1 Kinase Inhibition
Xian Chen, Kwang-Huei Low, Angela Alexander, et al.
Oncotarget
|
January 22, 2015
Functional consequence of the MET-T1010I polymorphism in breast cancer
Shuying Liu, Funda Meric-Bernstam, Napa Parinyanitikul, et al.
Future Oncology (London, England)
|
October 15, 2025
HERTHENA-PanTumor01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated advanced solid tumors
Thomas Powles, Aarti Bhatia, Barbara Burtness, et al.
Page
of 65
Search research articles
Search
Showing results (471-480 of 643) with videos related to
Sort By:
Page
of 65
Advances in Therapy
|
July 9, 2021
Pembrolizumab in Patients with Refractory Cutaneous Squamous Cell Carcinoma: A Phase II Trial
Renata Ferrarotto, Luana G Sousa, Yun Qing, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 25, 2022
Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib Study
Funda Meric-Bernstam, Randy F Sweis, Stefan Kasper, et al.
NPJ Precision Oncology
|
July 15, 2023
Actionability classification of variants of unknown significance correlates with functional effect
Amber Johnson, Patrick Kwok-Shing Ng, Michael Kahle, et al.
Cancer Discovery
|
February 15, 2024
Co-clinical Trial of Novel Bispecific Anti-HER2 Antibody Zanidatamab in Patient-Derived Xenografts
Timothy P DiPeri, Kurt W Evans, Bailiang Wang, et al.
International Journal of Cancer
|
November 13, 2019
Phase II, 2-stage, 2-arm, PIK3CA mutation stratified trial of MK-2206 in recurrent endometrial cancer
Andrea P Myers, Panagiotis A Konstantinopoulos, William T Barry, et al.
Investigational New Drugs
|
October 28, 2017
Radiomics to predict immunotherapy-induced pneumonitis: proof of concept
Rivka R Colen, Takeo Fujii, Mehmet Asim Bilen, et al.
American Journal of Cancer Research
|
January 8, 2021
KRT-232 and navitoclax enhance trametinib's anti-Cancer activity in non-small cell lung cancer patient-derived xenografts with KRAS mutations
Xiaoshan Zhang, Ran Zhang, Huiqin Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 6, 2018
Cyclin E Overexpression Sensitizes Triple-Negative Breast Cancer to Wee1 Kinase Inhibition
Xian Chen, Kwang-Huei Low, Angela Alexander, et al.
Oncotarget
|
January 22, 2015
Functional consequence of the MET-T1010I polymorphism in breast cancer
Shuying Liu, Funda Meric-Bernstam, Napa Parinyanitikul, et al.
Future Oncology (London, England)
|
October 15, 2025
HERTHENA-PanTumor01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated advanced solid tumors
Thomas Powles, Aarti Bhatia, Barbara Burtness, et al.
Page
of 65